Background: Initiating ART during acute/recent HIV-1 infection reduces viral reservoir formation. It has been proposed that, during this phase, the size of the viral reservoir could be further reduced by the association of immunomodulatory therapy with ART. Contradictory results have emerged, however, from two trials evaluating the impact on immune recovery and the viral reservoir of adding cyclosporine A to ART during primary HIV-1 infection.
Introduction
ART has raised life expectancy, reduced the incidence of opportunistic infections and improved the quality of life for HIV-infected patients. However, HIV-1 infection is still a chronic infection with a great number of associated complications and ART needs to be administered for life. 1 Therefore, searching for an HIV cure remains a priority. Two different forms of cure have been defined: a sterilizing cure, in which all replication-competent virus and infected cells are eliminated, and a functional cure, represented by the so-called 'elite controllers', who permanently control virus replication without ART. 2 The main obstacle in achieving functional cure is the persistence of a viral reservoir (VR), a pool of the HIV genome integrated into long-living T cells and probably into other cells such as macrophages. 3 This VR is established in a very early phase of the infection, probably during the first weeks.
It is known that early ART results in strong viral suppression rates and rapid recovery of the various subpopulations of CD4þ T cells and can reduce VR formation. [4] [5] [6] Immunomodulatory treatments in the early stages of infection have been proposed to decrease VR, presumably by decreasing immune activation and therefore the number of activated CD4þ T cells, the main target of HIV-1 infection. 7 Cyclosporine A (CsA) is an immunomodulatory drug that acts as a down-regulator of active CD4þ T cells by inhibiting IL-2 transcription, thus inhibiting the proliferation and activation of IL-2-dependent cells. 8, 9 In addition, some authors have proposed that CsA can act as a competitive inhibitor of cyclophilin A, a human peptidyl-prolyl isomerase that binds to the capsid of HIV-1, directly inhibiting the first steps of HIV-1 replication. 10, 11 Two previous trials explored the effect of CsA in acute/recent HIV infection with contradictory results. 12 , 13 Rizzardi et al. 12 presented a group of nine patients treated during acute/recent HIV-1 infection with ART (four drugs with two PIs) and CsA (dosed at 0.3-0.6 mg/kg/12h and target plasma levels of 250-450 lg/L during 8 weeks). This group was followed for 64 weeks and controlled with a retrospective cohort of patients with similar characteristics. The results of this trial were very encouraging, as a greater recovery in CD4þ T cells was observed in the ART þ CsA arm from week 1 of treatment and this difference was sustained over the 64 weeks of follow-up. No other differences were observed in proviral HIV-1 DNA, immunological responses or viral load decay. 12 Markowitz et al. 13 randomized 41 patients (1:2 ratio) to receive ART alone or in association with CsA for 4 weeks at a dose of 0.3 mg/kg with the same target plasma levels. In this trial, no differences were found in any of the variables measured (CD4þ T cell count, viral decay, immune response and proviral HIV-1 DNA in PBMCs). 13 Here, we report the results of a randomized clinical trial with patients enrolled during acute/recent HIV infection and assigned to receive standard ART or standard ART plus an 8 week course of CsA. The main hypothesis was that CsA initiated early enough could decrease VR formation and improve cell count recovery.
Methods

Design and interventions
In this randomized, exploratory, non-blinded, clinical trial, we enrolled adults >18 years old with an acute/recent HIV-1 infection (<180 days from the estimated date of infection) documented by one of the following criteria: a positive ELISA test with a previous negative test in the last 60 days; a positive ELISA test with a negative or indeterminate Western blot test and a high-risk contact in the last 60 days; or a positive ELISA test with a positive Western blot test and a negative detuned ELISA. In every case, HIV-1 infection was confirmed by a positive Western blot within 3 months of enrolment.
Patients were randomized using a computer-generated list of random numbers to ART alone (200 mg of emtricitabine once daily, 300 mg of tenofovir once daily plus 400/100 mg of lopinavir/ritonavir twice daily) or to ART plus 8 weeks of oral CsA (0.3-0.6 mg/kg twice daily with targeted plasma levels of 250-450 lg/L) initiated at the same time as ART (Figure 1 ). Plasma levels of CsA were measured on days 1 and 3 and then every week until week 8.
Patients from this study were included in a rollover trial, the design of which is explained in detail in ClinicalTrials.gov Identifier NCT00979706 (PHI-Immunomodulated; data not published). In the context of this rollover study, patients included in the ART þ CsA arm also received a single dose of GM-CSF (300 lg) and pegylated IFN (180 lg) at week 35 and then stopped ART at week 36. The rationale for this strategy was to improve antigenpresenting cell function during the first stop of ART. 14, 15 Twenty patients were enrolled on a 1:1 randomization basis during the years 2006 and 2008 in the Acute/Recent HIV-1 Clinic of the Hospital Clinic of Barcelona (Figure 1 ).
Follow-up
Screening included clinical assessment and laboratory evaluations: plasma HIV-1 RNA, T lymphocyte subsets, haematological tests and clinical biochemistry. After randomization, the evaluation included clinical visits at baseline, then weekly until week 8 and monthly thereafter until week 36. Plasma HIV-1 RNA was assessed at each visit. Viral resistance was performed at baseline and in cases of virological failure. VR (unintegrated and proviral HIV-1 DNA) was performed at baseline and weeks 8 and 36.
Outcomes and measurements
This study aimed to compare the median change in HIV-1 reservoir measured by unintegrated and proviral HIV-1 DNA at baseline and weeks 8 and 36. Secondary endpoints were undetectable plasma HIV-1 RNA at weeks 8 and 36 and CD4þ T cell recovery at weeks 8 and 36.
Virological studies
The baseline genotypic test results were obtained from all patients using the TrueGene HIV-1 assay system (Visible Genetics, Toronto, Canada). Plasma HIV-1 RNA copy levels were evaluated using the commercially available AMPLICOR quantitative RT-PCR assay (Roche Diagnostic Systems, Branchburg, NJ, USA) with a lower limit of detection of 50 copies/mL at baseline and every week.
Viral reservoir: total and proviral DNA Unintegrated and proviral DNA were measured at baseline and weeks 8 and 36 in PBMCs by a quantitative PCR assay as described previously 16 and expressed as the percentage change between baseline and week 8 and between weeks 8 and 36 and as the global change (between baseline and week 36).
Immunological studies
PBMCs were obtained by separation on a Ficoll-Hypaque (BiomedicsbioMérieux, Madrid, Spain) centrifugation gradient. Subpopulations of CD3þ, CD4þ and CD8þ cells were determined by flow cytometry at baseline, week 8 and week 36, respectively. The following monoclonal antibodies were used: CD3-peridinin chlorophyll protein (PerCP), CD4-PerCP, CD8-PerCP, CD4-FITC, CD8-phycoerythrin (PE), HLA DR-FITC, CD28-PE, CD38-PE, CD45RO-PE and CD45RA-FITC (all from Becton Dickinson, Mountain View, CA, USA). Mouse immunoglobulin isotypes conjugated with PerCP, PE or FITC were used systematically as negative controls for non-specific binding. The stained cells were analysed on a FACSCalibur (Becton Dickinson, San Jose, CA, USA) flow cytometer. Data were analysed using CELLQUEST software (Becton Dickinson).
PBMC proliferation assays were performed as described elsewhere. 17 PBMCs were washed twice and resuspended at 2 Â 10 6 /mL in protein-free medium X-VIVO 10. Cultures were performed in triplicate in 4 or 7 day Nicol as et al.
assays using 10 5 or 2 Â 10 5 cells/well in 96 round-bottomed microplates. Cells were cultured for 4 days in the absence or presence of phytohaemagglutinin (PHA) at 0.5% or recombinant HIV-1 proteins (p24 and gp160) at 5 lg/mL. Incorporation of tritium-labelled thymidine was assessed for the last 18 h of culture. Results are expressed as the stimulation index calculated for each sample as the ratio between the cpm for the stimulated cultures and the cpm for the non-stimulated cultures. Positive antigen-specific responses were defined as >3000 cpm and a stimulation index greater than three.
Statistics
Sample size was calculated for the PHI-Immunomodulated trial in order to detect a plasma viral load (pVL) difference of 1.5 log 10 copies/mL at 12 weeks (W56) after stopping HAART between the control and the immunebased arms with a power of 80% and a level of significance of 0.05.
Summary statistics were based on frequency and percentage, mean and 95% CI or median and IQR. The random-effects regression model was used to assess the change from baseline to weeks 8 and 36 and between treatment groups in virological, immunological, phenotype and proliferation measurements. Time and treatment group were the independent variables, along with the time Â group interaction term, representing the difference in differences (DID) estimator. In order to find the best nonlinear function over time of log 10 viral load, absolute CD4þ T cell count and percentage, the fractional polynomials were estimated, using all the measurements the individuals provided over the 36 weeks of follow-up considered for this study. Thereafter, random-effects regression with the transformed time variable, treatment group and interaction for the DID was assessed. All tests were two-tailed with a confidence level set to 95%. The statistical software used was Stata 13 (StataCorp, College Station, TX, USA).
Ethics
The study was approved by the Ethics Committee of the Hospital Clinic and by the Spanish Agency of Medicines and Medical Devices (AEMPS). All patients provided written informed consent.
Results
Baseline characteristics
Twenty patients were randomized (10 patients per arm) and all completed the trial. The baseline clinical and epidemiological characteristics of patients, listed in Table 1 , were comparable between both arms. Patients were predominantly men with a median age of 33.5 years in the ART-alone arm and 39.5 years in the ART þ CsA arm. The estimated median time from HIV infection to randomization was 70.8 days (IQR 58; 84.2) in the control group and 54 days (IQR 38; 68.5) in the treatment group (P ¼ 0.075). HIV subtype B was predominant in both groups (70% in both groups). Median HIV-1 RNA levels were comparable at baseline: 4.83 log 10 /mL (IQR 4.34; 5.69) in the treatment group versus 4.89 log 10 /mL (IQR 4.48; Cyclosporine A and ART during primary HIV-1 infection JAC 5.58) in the control group (P ¼ 0.87). Median absolute CD4þ T cell count and the rest of the T lymphocyte populations analysed were also comparable.
Viral reservoir
The mean decay of proviral HIV-1 DNA was comparable in the ART Table 2) .
Virological outcomes
The median viral load at week 8 was 2.31 log 10 /mL (95% CI 1.94; 2.68) in the ART þ CsA arm and 2.68 log 10 /mL (95% CI 2.29; 3.07) in the ART-alone arm with no significant difference between changes in both arms over time [DID ART þ CsA versus ART alone ¼ À0.25 (95% CI À0.89; 0.39), P ¼ 0.4413]. All 10 patients in each arm presented undetectable levels of HIV-1 RNA at week 16 and remained undetectable until week 36 (Table 2 ). Viral load decay fits a non-linear function of time (the inverse of square root of time). The DID estimator showed no differences between arms (Figure 2a) . No virological failures were recorded during the study.
CD4þ T cell recovery
No significant differences were found between the ART þ CsA arm and the ART-alone arm in absolute CD4þ T cell count recovery ei Figure  2b and c).
Immune response
There were significant group differences at weeks 8 and 36 in proliferative responses to HIV antigens (p24). Namely, in the ART þ CsA group there was an increased response to p24 at week 36 in comparison with ART alone (DID ART þ CsA versus ART alone between weeks 36 and 8 and weeks 36 and 0: 5.452 and 4.171 with P ¼ 0.0038 and 0.0214, respectively). Regarding T cell subsets (CD28þ or CD38þ/HLA-DRþ in CD4þ and CD8þ T cells), there were no significant differences between arms. CD8 T cell activation (CD8þCD38þ and CD8þCD38þDRþ cells), as expected after HAART initiation, was reduced in both arms (Table 3) . Nicol as et al.
Safety outcomes
None of the patients in the ART þ CsA arm presented any moderate or severe adverse event or required treatment interruption. CsA was well tolerated by the 10 patients in the ART þ CsA arm and they all achieved therapeutic plasma levels of the drug. (Table 4) .
Discussion
The aim of this exploratory trial was to investigate the potential effect on the establishment of VR of CsA administered together with early-started ART during acute/recent HIV infection. Potentially, CsA could slow down and block the spread of HIV-1 in the organism by acting at two levels: (i) inhibiting IL-2 production and reducing the number of IL-2-dependent activations and the proliferation of CD4þ T cells; 8, 9 and (ii) competing with cyclophilin A and therefore blocking the assembly of the capsid of the virus. 10, 11 Given that activated and proliferating CD4þ T cells are the main target for HIV replication, 7 it would seem plausible to observe a reduction in VR establishment when using CsA during early HIV-1 infection. Two previous trials explored the effect of CsA in acute/recent HIV infection, with different results. Rizzardi et al.
12 observed a greater recovery in CD4þ T cells in the CsA group, but these results were not confirmed by Markowitz et al., 13 who did not find any differences between groups in immune recovery or proviral HIV-1 DNA.
Our study is the first to explore the effect of CsA in both integrated (proviral) and non-integrated HIV-1 DNA. Our primary endpoint was to compare decay in VR (proviral HIV-1 DNA in PBMCs) after CsA treatment administration. Other possible findings were a better recovery in CD4þ cells and a faster decay in Cyclosporine A and ART during primary HIV-1 infection JAC the HIV-1 RNA slope during the first 8 weeks of treatment. Conversely to Rizzardi et al., 12 no significant difference in CD4 count was found between arms either at week 8 or week 36. Absolute CD4 presented a non-significant decrease in the CsA arm over time. In contrast, as can be seen in Figure 2(c) , when observing CD4 percentage, this non-significant difference is inverted, with a higher percentage of CD4 in the CsA arm. In fact, when comparing the CD4/CD8 ratio between arms, a better, although not significant recovery ratio was observed in the CsA arm. These results are probably due to a decreasing effect of CsA on global lymphocytes. Viral load decreased in both arms with a comparable trend. The effect of CsA on VR formation was very limited; the decay of proviral DNA after 8 weeks of CsA treatment did not lead to any differences between groups. When measuring unintegrated DNA, some different and interesting results were observed. There was a non-significant trend towards a rise in levels of non-integrated DNA at week 8 in the ART þ CsA arm and these increased levels persisted at week 36 and became statistically significant. This finding could indicate an anti-integration effect of CsA that persisted beyond CsA treatment stop, although this was not associated with a greater reduction in integrated HIV-1 DNA. However, the patients in the ART þ CsA group also received a dose of GM-CSF and pegylated IFN at week 35 and it is not possible to exclude the potential role of this intervention in the results found at week 36.
Regarding the immunological data, some patients had improved lymphoproliferative responses to mitogens, with significant differences between the two arms at week 8. The association between markers of immune activation and progression to clinical AIDS is well known and the intensity of CD38 staining on CD8þ T cells is the most strongly correlated parameter. Furthermore, several studies have assessed the evolution of immune activation on ART and its correlation with the control of viral replication. 18 The global decrease in immune activation observed in this study was similar in both the ART-alone and ART þ CsA groups.
This study presents some limitations. The first is the limited sample size, as the study was initially exploratory in nature. This limits the extrapolation of the results to larger populations. Second, patients in the ART þ CsA group also received one dose of GM-CSF and pegylated IFN at week 35, so it is not possible to exclude the potential role of this intervention in causing the increased lymphoproliferative response to HIV p24 and higher levels of nonintegrated HIV DNA, an issue that deserves further investigation.
In conclusion, adding CsA to ART started during acute/recent HIV-1 infection was not associated with a clinical benefit to standard treatment in terms of immunological outcome, although the lymphoproliferative response to HIV p24 Ag did increase in the ART þ CsA arm at week 36. Viral load decay was similar in both groups. No differences were observed in proviral DNA, but the increased levels of non-integrated HIV DNA in the ART þ CsA arm at week 36 might suggest a possible anti-integration effect of CsA.
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